FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2040542666> ?p ?o ?g. }

• W2040542666 endingPage "1275" @default.
• W2040542666 startingPage "1265" @default.
• W2040542666 abstract "The intestinal barrier becomes compromised during systemic inflammation, leading to the entry of luminal bacteria into the host and gut origin sepsis. Pathogenesis and treatment of inflammatory gut barrier failure is an important problem in critical care. In this study, we examined the role of cyclooxygenase-2 (COX-2), a key enzyme in the production of inflammatory prostanoids, in gut barrier failure during experimental peritonitis in mice. I.p. injection of LPS or cecal ligation and puncture (CLP) increased the levels of COX-2 and its product prostaglandin E2 (PGE2) in the ileal mucosa, caused pathologic sloughing of the intestinal epithelium, increased passage of FITC-dextran and bacterial translocation across the barrier, and increased internalization of the tight junction (TJ)-associated proteins junction-associated molecule-A and zonula occludens-1. Luminal instillation of PGE2 in an isolated ileal loop increased transepithelial passage of FITC-dextran. Low doses (0.5-1 mg/kg), but not a higher dose (5 mg/kg) of the specific COX-2 inhibitor Celecoxib partially ameliorated the inflammatory gut barrier failure. These results demonstrate that high levels of COX-2-derived PGE2 seen in the mucosa during peritonitis contribute to gut barrier failure, presumably by compromising TJs. Low doses of specific COX-2 inhibitors may blunt this effect while preserving the homeostatic function of COX-2-derived prostanoids. Low doses of COX-2 inhibitors may find use as an adjunct barrier-protecting therapy in critically ill patients." @default.
• W2040542666 created "2016-06-24" @default.
• W2040542666 creator A5004364763 @default.
• W2040542666 creator A5005083308 @default.
• W2040542666 creator A5015247273 @default.
• W2040542666 creator A5018244700 @default.
• W2040542666 creator A5025009803 @default.
• W2040542666 creator A5028357759 @default.
• W2040542666 creator A5039038490 @default.
• W2040542666 creator A5041497800 @default.
• W2040542666 creator A5057671752 @default.
• W2040542666 creator A5075528595 @default.
• W2040542666 date "2013-12-01" @default.
• W2040542666 modified "2023-10-10" @default.
• W2040542666 title "Low doses of Celecoxib attenuate gut barrier failure during experimental peritonitis" @default.
• W2040542666 cites W1460228636 @default.
• W2040542666 cites W1487384673 @default.
• W2040542666 cites W1499179353 @default.
• W2040542666 cites W1512081113 @default.
• W2040542666 cites W1762434727 @default.
• W2040542666 cites W1932880974 @default.
• W2040542666 cites W1940681873 @default.
• W2040542666 cites W1951711480 @default.
• W2040542666 cites W1964661002 @default.
• W2040542666 cites W1967120011 @default.
• W2040542666 cites W1970860938 @default.
• W2040542666 cites W1971217567 @default.
• W2040542666 cites W1972899659 @default.
• W2040542666 cites W1973299402 @default.
• W2040542666 cites W1978345057 @default.
• W2040542666 cites W1989432109 @default.
• W2040542666 cites W1989588261 @default.
• W2040542666 cites W1992490895 @default.
• W2040542666 cites W1997123421 @default.
• W2040542666 cites W2000049046 @default.
• W2040542666 cites W2004131035 @default.
• W2040542666 cites W2006194008 @default.
• W2040542666 cites W2006517042 @default.
• W2040542666 cites W2009205583 @default.
• W2040542666 cites W2012354170 @default.
• W2040542666 cites W2012849769 @default.
• W2040542666 cites W2013860391 @default.
• W2040542666 cites W2018440490 @default.
• W2040542666 cites W2019581966 @default.
• W2040542666 cites W2019766373 @default.
• W2040542666 cites W2020430786 @default.
• W2040542666 cites W2023532695 @default.
• W2040542666 cites W2026784872 @default.
• W2040542666 cites W2028950494 @default.
• W2040542666 cites W2036863530 @default.
• W2040542666 cites W2039895555 @default.
• W2040542666 cites W2050322036 @default.
• W2040542666 cites W2057106111 @default.
• W2040542666 cites W2057948332 @default.
• W2040542666 cites W2061583677 @default.
• W2040542666 cites W2065511858 @default.
• W2040542666 cites W2067491481 @default.
• W2040542666 cites W2068294585 @default.
• W2040542666 cites W2069780385 @default.
• W2040542666 cites W2075850600 @default.
• W2040542666 cites W2082256599 @default.
• W2040542666 cites W2085274710 @default.
• W2040542666 cites W2085429049 @default.
• W2040542666 cites W2085966326 @default.
• W2040542666 cites W2088713567 @default.
• W2040542666 cites W2089044394 @default.
• W2040542666 cites W2098087741 @default.
• W2040542666 cites W2103536507 @default.
• W2040542666 cites W2111648846 @default.
• W2040542666 cites W2113204284 @default.
• W2040542666 cites W2114711171 @default.
• W2040542666 cites W2120351662 @default.
• W2040542666 cites W2121414029 @default.
• W2040542666 cites W2121836743 @default.
• W2040542666 cites W2122039020 @default.
• W2040542666 cites W2133644846 @default.
• W2040542666 cites W2133872620 @default.
• W2040542666 cites W2133926520 @default.
• W2040542666 cites W2141343882 @default.
• W2040542666 cites W2143955916 @default.
• W2040542666 cites W2144415706 @default.
• W2040542666 cites W2152213031 @default.
• W2040542666 cites W2152456210 @default.
• W2040542666 cites W2167054765 @default.
• W2040542666 cites W2167527242 @default.
• W2040542666 cites W2171690203 @default.
• W2040542666 cites W2171971109 @default.
• W2040542666 cites W2172015504 @default.
• W2040542666 cites W2331217668 @default.
• W2040542666 cites W2412442244 @default.
• W2040542666 cites W2415316809 @default.
• W2040542666 cites W2417575008 @default.
• W2040542666 cites W2441169818 @default.
• W2040542666 cites W80472240 @default.
• W2040542666 doi "https://doi.org/10.1038/labinvest.2013.119" @default.
• W2040542666 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3966546" @default.
• W2040542666 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24126890" @default.
• W2040542666 hasPublicationYear "2013" @default.

• next